Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Issues Quarterly Earnings Results, Beats Expectations By $1.01 EPS

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) issued its quarterly earnings data on Monday. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $1.01, FiscalAI reports. The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $7.29 million.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Shares of LKFT stock traded down $0.09 on Monday, reaching $26.91. 158,430 shares of the company were exchanged, compared to its average volume of 158,908. Lakefront Biotherapeutics American Depositary Shares has a 1 year low of $25.68 and a 1 year high of $37.78. The business has a 50-day moving average price of $28.67 and a 200 day moving average price of $30.16. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -19.09 and a beta of 0.27.

Analysts Set New Price Targets

Several equities analysts recently weighed in on LKFT shares. Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Morgan Stanley began coverage on Lakefront Biotherapeutics American Depositary Shares in a report on Friday, July 10th. They issued an “equal weight” rating and a $30.00 price objective on the stock. Weiss Ratings cut Lakefront Biotherapeutics American Depositary Shares from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 4th. Finally, Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $34.33.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

Institutional investors have recently bought and sold shares of the company. State of Wyoming acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the second quarter valued at approximately $28,000. Van ECK Associates Corp increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% during the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 750 shares in the last quarter. Arax Advisory Partners increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% during the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 1,778 shares in the last quarter. Quadrant Capital Group LLC acquired a new position in Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at $134,000. Finally, Squarepoint Ops LLC acquired a new position in Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at $211,000. 32.46% of the stock is currently owned by institutional investors and hedge funds.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.